Lung cancer

Chemotherapy

PD-L1

Immunotherapy

Pembrolizumab

Cancer

Internal medicine

Oncology

Medicine

New England Journal of Medicine

Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer